{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:19:38Z","timestamp":1740125978532,"version":"3.37.3"},"reference-count":86,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy and safety of biologic response modifiers such as etanercept, adalimumab, infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults, but none are currently approved for the treatment of psoriasis in children in the United States, and only etanercept is approved for the treatment of psoriasis in children in the European Union. Through case reports, case series, and a large clinical trial of the use of etanercept, the literature supports the use of these agents to treat psoriasis in children. Data on the use of the tumor necrosis factor\u2010\u03b1 antagonists etanercept, adalimumab, and infliximab in the treatment of other inflammatory diseases in children\u2014namely Crohn's disease, juvenile arthritis, and uveitis\u2014support their safety profile in children.<\/jats:p>","DOI":"10.1111\/pde.12547","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T11:03:18Z","timestamp":1424948598000},"page":"303-320","source":"Crossref","is-referenced-by-count":14,"title":["Biologic Response Modifiers and Pediatric Psoriasis"],"prefix":"10.1111","volume":"32","author":[{"given":"Fernanda","family":"Bellodi Schmidt","sequence":"first","affiliation":[{"name":"Division of Dermatology Cincinnati Children's Hospital Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-9541","authenticated-orcid":false,"given":"Kara N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Dermatology Cincinnati Children's Hospital Cincinnati Ohio"},{"name":"Department of Dermatology College of Medicine University of Cincinnati Cincinnati Ohio"},{"name":"Department of Pediatrics College of Medicine University of Cincinnati Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12205"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.013"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.5070\/D33N39N8XM"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11208.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27511"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-8-18"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.026"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.040"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12065"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2006.00174.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2012.12.005"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06982.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(10)70009-0"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03081.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.01.064"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1540"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D33XF9F397","article-title":"Successful use of infliximab following a failed course of etanercept in a pediatric patient","volume":"11","author":"Farnsworth NN","year":"2005","journal-title":"Dermatol Online J"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/ejd.2010.1177","article-title":"Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis","volume":"21","author":"Fotiadou C","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962011000700038"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1684\/ejd.2011.1432","article-title":"Etanercept, childhood and long\u2010term safety: a case of five years treatment","volume":"21","author":"Mazzotta A","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096202"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01234.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500430604"},{"key":"e_1_2_10_33_1","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged > or = 8\u00a0years with severe plaque psoriasis","volume":"20","author":"Landells I","year":"2010","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.060"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.004"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066886"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.046"},{"key":"e_1_2_10_38_1","unstructured":"Study evaluating the safety and effectiveness of etanercept for the treatment of pediatric psoriasis (PURPOSE)[online].http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01100034?term=purpose+etanercept&rank=1. Accessed on December 28 2014."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10710"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23427"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21885"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12404"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13004"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00971.x"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams J","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0736-8046.2004.21121.x"},{"key":"e_1_2_10_55_1","first-page":"1","article-title":"The evolving role of biologics in the treatment of pediatric psoriasis","volume":"18","author":"Luu M","year":"2013","journal-title":"Skin Ther Lett"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01219.x"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.12.005"},{"key":"e_1_2_10_59_1","unstructured":"A double blind study in pediatric subjects with chronic plaque psoriasis studying adalimumab versus methotrexate[online].http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01251614. Accessed on December 26 2014."},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.046"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2082-5"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04603.x"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.103721"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.493"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.058"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12046"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.041"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.011"},{"key":"e_1_2_10_72_1","first-page":"300","article-title":"An update on the long\u2010term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow\u2010up","volume":"11","author":"Reich K","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_10_73_1","unstructured":"A phase 3 multicenter randomized double\u2010blind placebo\u2010controlled study evaluating the efficacy and safety of ustekinumab in the treatment of adolescent subjects with moderate to severe plaque\u2010type psoriasis (CADMUS) [online].https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01090427. Accessed on December 28 2014."},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.04.003"},{"key":"e_1_2_10_75_1","first-page":"278","article-title":"[Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease]","volume":"70","author":"Avila AA","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182802c93"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20450"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2012.02.008"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181f3d9ab"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049916"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01521.x"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8262-2"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01267.x"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000088"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31828390ba"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.372"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09329.x"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12547","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:05:12Z","timestamp":1696165512000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/pde.12547"],"URL":"https:\/\/doi.org\/10.1111\/pde.12547","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"type":"print","value":"0736-8046"},{"type":"electronic","value":"1525-1470"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}